The Endpoints 11: They've got mad money and huge ambitions. It's time to go big or go home
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma. I’ve had a couple of faceplants earlier this year, watching some of the biotechs on my short list choose a quick leap onto Nasdaq or into the arms of a buyer.
Vividion, you would have been a great pick for the Endpoints 11. I’m sorry I missed you.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.